On 4 February, Pharvaris N.V. announced the pricing of its underwritten IPO for an amount up to USD 190 million in new common shares. The deal was upsized and priced above the price range. NautaDutilh already assisted Pharvaris with its Series B financing round in 2019 and with its Series C financing cross-over round in 2020. NautaDutilh acted alongside Kirkland & Ellis (US counsel to Pharvaris).
Pharvaris is a clinical-stage company focused on bringing oral bradykinin B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.
For the press release by Pharvaris, please click here.